Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine | Strategic Alliance Partners

At Northwestern Medicine, we put our patients first in an effort to deliver the best cancer care. Our teams of experts are here to help support patients and their caregivers during all stages of their cancer journey: diagnosis, treatment, and recovery.

Northwestern Medicine’s cancer centers provide access to state-of-the art therapies and comprehensive cancer care offering leading-edge medical, surgical and radiation oncology treatment options, as well as access to specialized research, clinical trials and diagnostic services.

Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is proud to be ranked as one of the top 8 cancer programs in the country by U.S. News & World Report.

Latest from Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine


PSA Responses to Enzalutamide Significantly Associated With Longer MFS in nmCRPC

October 01, 2020

Maha H.A. Hussain, MD, FACP, FASCO, discusses the prognostic associations of depth of PSA responses with MFS in patients with nmCRPC and a rapidly rising PSA who have been treated with enzalutamide and other efforts being made in this disease.

Trastuzumab Deruxtecan Shows Broad Benefit in Metastatic HER2+ Breast Cancer

July 13, 2020

William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.

Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer

June 11, 2020

In our exclusive interview, Dr. Gradishar shares the path that led him to specialize in the field of breast cancer, collective experiences that have inspired him throughout his career, and his hope for the continued transition from “shotgun medicine” to precision medicine in the field.

Talking Tumors: Treating With Immunotherapy and Targeted Therapy in Lung Cancer

April 20, 2020

Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.

Dr. Hussain on the Implications of the PROfound Trial in mCRPC

March 28, 2020

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).